MyFinsight
Home
Blog
About
Proceeds from the
issuance of common stock...
$108,080K
Proceeds from the
issuance of common stock...
$425K
(19.05%↑ Y/Y)
Proceeds from the
exercise of stock options
$230K
Net cash provided by
financing activities
$108,735K
(4671.17%↑ Y/Y)
Net decrease in cash
and cash...
$1,166K
(108.13%↑ Y/Y)
Canceled cashflow
$107,569K
Proceeds from maturities
of marketable...
$53,755K
(-11.78%↓ Y/Y)
Stock-based compensation
$2,416K
(56.27%↑ Y/Y)
Other accrued
expenses
$678K
(119.62%↑ Y/Y)
Accrued research and
development expenses
$469K
(180.58%↑ Y/Y)
Non-cash rent expense
$203K
(-53.65%↓ Y/Y)
Depreciation and
amortization
$20K
(-69.23%↓ Y/Y)
Net cash (used in)
provided by investing...
-$92,081K
(-490.50%↓ Y/Y)
Net cash used in
operating activities
-$15,488K
(61.47%↑ Y/Y)
Canceled cashflow
$53,755K
Canceled cashflow
$3,786K
Collaboration revenue from a
related party
$13,374K
Interest and other
income, net
$2,487K
Purchases of marketable
securities
$145,836K
(290.44%↑ Y/Y)
Deferred revenue from a
related party
-$12,772K
(32.94%↑ Y/Y)
Net loss
-$3,857K
(79.72%↑ Y/Y)
Canceled cashflow
$15,861K
Prepaid expenses and
other current assets
$1,234K
(231.70%↑ Y/Y)
Net accretion of
investments in marketable...
$768K
(-13.42%↓ Y/Y)
Accounts receivable from
collaboration with a related...
$371K
Operating lease
liabilities
-$202K
(43.26%↑ Y/Y)
Accounts payable
-$70K
(-144.30%↓ Y/Y)
Total research and
development
$14,917K
General and
administrative
$4,801K
Back
Back
Cash Flow
ASSEMBLY BIOSCIENCES, INC. (ASMB)
ASSEMBLY BIOSCIENCES, INC. (ASMB)
source: myfinsight.com